Rallybio Corp (RLYB) Financials
Annual revenue, profitability and per-share results for Rallybio Corp, as reported in SEC filings.
Revenue • FY2025
$858K
▲ 43.0%YoY
Net income • FY2025
-$8.98M
▲ 84.5%YoY
Diluted EPS • FY2025
-$1.59
▼ 19.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $858K | -$8.98M | — | -$1.59 | — | -3853.6% | +43.0% |
| FY2024 | $600K | -$57.77M | — | -$1.33 | -$49.28M | -10082.7% | — |
| FY2023 | $0 | -$74.56M | — | -$1.84 | -$60.28M | — | — |
| FY2022 | $0 | -$66.65M | — | -$2.09 | -$57.34M | — | — |
Figures as reported in Rallybio Corp's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a RLYB filing.
Get an email when RLYB files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.